Sanaria Inc. Receives Multi-Year U.S. NIH Phase II Small Business Innovation Research Grant to Develop a Genetically Attenuated Whole Parasite Malaria Vaccine

ROCKVILLE, Maryland, February 23, 2010 - Sanaria Inc. has received additional support from the National Institute
of Allergy and Infectious Diseases (NIAID) of the National Institutes of
Health in the form of a Phase II Small Business Innovation Research (SBIR)
Grant. The three-year award totaling approximately US$3 million will support
collaborative research by investigators at Sanaria and Columbia University.
This new funding extends previous NIAID supported efforts at Sanaria and
Columbia to develop genetically modified strains of the human malaria
parasite Plasmodium falciparum that are unable to cause disease, yet
stimulate protective immunity when administered as a live, whole parasite
malaria vaccine. "There is considerable excitement about whole parasite
malaria vaccines, and research towards developing genetically modified
strains for such vaccines is at the cutting edge of this field," states Dr.
Christian Loucq, Director of the PATH Malaria Vaccine Initiative.

Sporozoite stage parasites that have been weakened (attenuated) by
exposure to radiation confer high-level protection against malaria when
introduced by the bite of infected mosquitoes. The attenuated parasites
invade host tissues, but cannot complete differentiation and therefore do not
replicate or cause disease. Sanaria has developed technologies and built a
facility to manufacture a radiation attenuated sporozoite vaccine that can be
administered by injection and has met FDA regulatory standards for initial
clinical evaluation. This vaccine candidate, the SanariaTM PfSPZ Vaccine, is
now being assessed in clinical trials. According to Dr. Stephen L. Hoffman,
Sanaria's founder and chief scientist, "Sanaria is uniquely positioned at
this time to expand the pipeline of candidate sporozoite vaccines to include
vaccines based on precisely gene-altered parasites that are highly potent in
inducing protective immunity against malaria and are unable to cause
disease."

"Sanaria's proven ability to manufacture whole sporozoite vaccines in
compliance with FDA standards means that promising new strains of the malaria
parasite that are being developed in our research laboratory can be
efficiently translated into prototype candidate vaccines suitable for testing
in the clinic," says Dr. David Fidock of Columbia University. Dr. Robert
Sauerwein of the Radboud University Nijmegen Medical Centre, whose laboratory
in collaboration with Sanaria has generated several genetically attenuated
strains of Plasmodium falciparum concurs, stating, "This is a very exciting
opportunity to make significant strides that will facilitate translation from
the laboratory to clinical studies of a vialed, genetically attenuated,
sporozoite vaccine inoculated by needle and syringe."

About Sanaria Inc.

Sanaria Inc. was founded in 2003. The company's primary mission is to
develop and commercialize attenuated whole-parasite malaria vaccines that
confer high-level, long-lasting protection against Plasmodium falciparum, the
parasite responsible for most of the malaria-associated severe illness and
death worldwide. Sanaria's radiation attenuated sporozoite vaccine,
Sanaria(TM) PfSPZ Vaccine, entered clinical trials in 2009. Sanaria's
corporate headquarters, administrative, research, development, and
manufacturing operations are located in Rockville, Maryland. The company's
Web site is www.sanaria.com.

Except for historical information, this news release contains certain
forward-looking statements that involve known and unknown risk and
uncertainties, which may cause actual results to differ materially from any
future results, performance or achievements expressed or implied by the
statements made. These forward-looking statements are further qualified by
important factors that could cause actual results to differ materially from
those in the forward-looking statements.

    For further information contact:
    Media- Adam Richman +1-301-770-3222,
    Investors- Robert Thompson +1-240-403-2750

Adam Richman, +1-301-770-3222